Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.
Recent news :
Dec 2025 – Affilogic’s CEO presenting at CNS Drug Delivery Summit : Olivier Kitten is presenting at CNS Drug Delivery Summit in Boston latest in-vivo data on our Bus2Brain program, using Nanofitins® for the delivery of biologics into the brain.
Nov 2025 – Affilogic’s CSO presenting latest data on our Orally delivered Nanofitins : Mathieu Cinier is presenting at PEGS EUROPE 2025 latest in-vivo data on our GiJob program.
Around the world
World ADC LONDON 2026
Affilogic is presenting a poster at next World ADC LONDON 2026 in London – UK
Feb 23-66, 2026
BiotechShowcase / JPM 2026
Affilogic attending next BiotechShowcase/JPM week in San-Francisco- USA
Jan 12-16, 2026
CNS Drug Delivery Summit 2025
We are presenting at next CNS Drug Delivery Summit in Boston- USA
Dec 09-11, 2025
Nanofitins
Each Nanofitin® is 20 times smaller than an antibody and demonstrates hyper stability. Their simple protein scaffold is particularly fitted for combination.
Read More
Our Programs
Affilogic develops therapeutic programs leveraging unique Nanofitins’ properties for brain delivery, inhalation of antivirals, oral GI treatments or small size drug conjugates.
Read More
NanoVector
Affilogic works with partners to deliver their therapeutic compounds to specific cells / organs with existing Nanofitins® or through custom generation of Nanofitins®.
Read More